Log in to your Inderes Free account to see all free content on this page.
Lipigon Pharmaceuticals
0.01 SEK
-5.71 %
Less than 1K followers
LPGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Lipigon Pharmaceuticals
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | 1.7 | 4.0 | 2.2 | 16.4 | 10.3 | |
| growth-% | 130.2 % | -44.9 % | -37.3 % | |||
| EBITDA | -4.9 | -7.8 | -41.2 | -37.7 | -12.4 | -25.5 |
| EBIT | -4.9 | -7.8 | -41.2 | -37.7 | -12.4 | -25.6 |
| Profit before taxes | -5.0 | -8.1 | -41.1 | -37.7 | -12.1 | -25.3 |
| Net income | -5.0 | -8.1 | -41.1 | -37.7 | -12.1 | -25.3 |
| EPS | -0.29 | -0.47 | -2.38 | -1.63 | -0.15 | -0.14 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| EBITDA-% | -283.2 % | -195.1 % | -1,862.0 % | -75.3 % | -248.0 % | |
| EBIT-% | -283.2 % | -195.1 % | -1,863.0 % | -75.4 % | -248.6 % | |
| ROE | -229.9 % | -62.1 % | -179.0 % | -974.4 % | -42.6 % | -325.5 % |
| ROI | -155.3 % | -52.9 % | -139.7 % | -348.5 % | -36.1 % | -170.4 % |
Login required
This content is only available for logged in users